@Relmada Therapeutics: A Promising Depression Focused Player For 2020
Feb. 17, 2020 10:08 AM ETRelmada Therapeutics, Inc. (RLMD)AXSM, VTGN2 Comments
Relmada Therapeutics' lead asset, REL-1017 can be a game-changer in depression indication.
The company has sufficient funds to sustain its operations.
Investors should consider risks such as business concentration risk, R&D failure risk, and commercial uptake uncertainties.
Today, we will study why Relmada Therapeutics (NASDAQ:RLMD) is an attractive clinical-stage biopharmaceutical pick in 2020.”
REL-1017 can offer a more effective yet safer treatment option for TRD patients
In 2017, there were 17.3 million MDD (major depressive disorder) patients in the U.S. Of these, 10% - 30% suffer from TRD (treatment-resistant depression). NMDA antagonists are fast emerging as a potent class of drugs in the depression indication. REL-1017 can prove to be equal or even superior to the much-touted Ketamine with a stronger safety profile as an antidepressant for TRD patients.
....Like Ketamine, D-methadone seems to possess NMDA antagonist properties which have an anti-depressant effect. This was seen in three animal models of depression. The drug's Phase 1 trial also demonstrated a favourable safety and tolerability profile of the drug. D-methadone has not demonstrated adverse events associated with traditional opioid or ketamine at the expected therapeutic doses. D-methadone is an isomer of racemic methadone.
Normally, racemic methadone is associated with common opioid side effects such as anxiety, nervousness, restlessness, sleep problems (insomnia), nausea, vomiting, constipation, diarrhoea, drowsiness, and others. Published literature shows that left or Levo isomer, l-methadone, is largely is related to opioid activity, while the right or Dextro isomer, d-methadone, has less of that activity.
If approved, Dextromethadone may be a more convenient treatment option in terms of its dosing regimen and route of administration.
REL-1017 has demonstrated robust efficacy and safety in Phase 2 trial
On October 15, Relmada Therapeutics announced positive topline data from Phase 2 REL-1017-202, study evaluating two dosages, 25 mg once a day and 50 mg once a day, of REL-1017 as an adjunctive treatment option for TRD patients....